{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:53:17Z","timestamp":1779112397606,"version":"3.51.4"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"American Academy of Neurology Annual Meeting"},{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Central nervous system (CNS) tumors often harbor alterations in genes regulating key cellular pathways, including fibroblast growth factor receptor (FGFR) genes. Here, we report the efficacy and safety of treatment with pemigatinib, an oral, potent, selective FGFR1-3 inhibitor, in patients with advanced FGFR-altered CNS tumors. FIGHT-207 was a single-arm, open-label, phase 2 study of pemigatinib in patients with advanced solid tumors harboring FGFR fusions\/rearrangements or other mutations. Patients received pemigatinib 13.5\u2009mg once daily until disease progression or unacceptable toxicity. Endpoints included tumor response and safety. Of the 13 patients with CNS tumors in FIGHT-207, 10 had glioblastoma. Fibroblast growth factor receptor alterations were FGFR3-TACC3 fusions (n\u2009=\u20099), FGFR1 K656E mutations (n\u2009=\u20092), FGFR1 N546K mutation (n\u2009=\u20091), and FGFR1-MITF fusion (n\u2009=\u20091). Three patients (23%) displayed objective responses (1 complete, 2 partial). Safety was consistent with the overall FIGHT-207 population. Pemigatinib had antitumor activity and a manageable safety profile in patients with CNS tumors.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf272","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:16:25Z","timestamp":1760616985000},"source":"Crossref","is-referenced-by-count":2,"title":["Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-2630","authenticated-orcid":false,"given":"Iben","family":"Spanggaard","sequence":"first","affiliation":[{"name":"Department of Oncology, Rigshospitalet Copenhagen University Hospital , Copenhagen 2100,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Matrana","sequence":"additional","affiliation":[{"name":"Ochsner Cancer Institute, Ochsner Clinic Foundation , New Orleans, LA 70121,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio","family":"Rocha Lima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Wake Forest University School of Medicine\u2014Atrium Health , Winston-Salem, NC 27157,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]},{"name":"Seidman Cancer Center, Case Western Reserve University , Cleveland, OH 44106,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vieito","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d\u2019Hebron University Hospital , Barcelona 08035,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Hervieu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Georges-Fran\u00e7ois Leclerc , Dijon 21000,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lipika","family":"Goyal","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center, Harvard Medical School , Boston, MA 02114,","place":["United States"]},{"name":"Stanford Cancer Center, Stanford School of Medicine , Stanford, CA 94305,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rod\u00f3n","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, The University of Texas , Houston, TX 77030,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Veronese","sequence":"additional","affiliation":[{"name":"Incyte International Biosciences S\u00e0rl , Morges 1110,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Incyte International Biosciences S\u00e0rl , Morges 1110,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE 19803,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Incyte Corporation , Wilmington, DE 19803,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[{"name":"Providence Southern California Research Clinical Institute, Saint John\u2019s Cancer Institute, Pacific Neuroscience Institute, Los Angeles, CA 90404,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2025112211170837700_oyaf272-B1","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med"},{"key":"2025112211170837700_oyaf272-B2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11910-021-01152-9","article-title":"Epidemiology of brain and other CNS tumors","volume":"21","author":"Ostrom","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025112211170837700_oyaf272-B3","doi-asserted-by":"crossref","first-page":"100641","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"key":"2025112211170837700_oyaf272-B4","volume-title":"Full Prescribing Information, Incyte Corporation","author":"PEMAZYRE","year":"2022"},{"key":"2025112211170837700_oyaf272-B5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3390\/cancers13051147","article-title":"TERT promoter alterations in glioblastoma: a systematic review","volume":"13","author":"Olympios","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025112211170837700_oyaf272-B6","doi-asserted-by":"crossref","first-page":"vii80","DOI":"10.1093\/neuonc\/noac209.304","article-title":"CTNI-39. FIGHT-209: a phase 2, open-label, multicentre study of pemigatinib in patients with previously treated glioblastoma or other primary central nervous system tumors with activating FGFR1-3 alterations","volume":"24","author":"Ahluwalia","year":"2022","journal-title":"Neuro Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf272\/64717747\/oyaf272.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf272\/64717747\/oyaf272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf272\/64717747\/oyaf272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:17:16Z","timestamp":1763828236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf272\/8287637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":6,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf272","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,16]]},"article-number":"oyaf272"}}